Serum CRP, IL-17A, and IL-17F levels are responsive to ustekinumab in psoriatic arthritis: lessons from the PSUMMIT study programme

Systemic Lupus Erythematosus

Response to ustekinumab treatment in patients with systemic lupus erythematosus is linked to suppression of serum interferon gamma levels

Arthritis Rheumatol

Cesaroni M, Seridi L, Loza MJ, Schreiter J, Sweet K, Franks C, Ma K, Orillion A, Campbell K, Gordon R, Branigan P, Lipsky P, van Vollenhoven R, Hahn BH, Tsokos GC, Chevrier M, Rose S, Baribaud F, Jordan J

doi: 10.1002/art.41547

Psoriatic ArthritisRheumatoid ArthritisSpinal Disorders

Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study

Arthritis Res Ther.

Gehin JE, Goll GL, Warren DJ, Syversen SW, Sexton J, Strand EK, Kvien TK, Bolstad N, Lie E

doi: 10.1186/s13075-019-2009-5.

Psoriatic ArthritisRheumatoid Arthritis

Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis

Rheumatology (Oxford).

Genovese MC, Weinblatt ME, Mease PJ, Aelion JA, Peloso PM, Chen K, Li Y, Liu J, Othman AA, Khatri A, Mansikka HT, Leszczynski P

doi: 10.1093/

Psoriasis

Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis

JAMA Dermatol.

Tsakok T, Wilson N, Dand N, Loeff FC, Bloem K, Baudry D, Duckworth M, Pan S, Pushpa-Rajah A, Standing JF, de Vries A, Alsharqi A, Becher G, Murphy R, Wahie S, Wright A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, Burden AD, Rispens T, Stocken D, Smith C, British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) Study Group and the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) Consortium.

doi: 10.1001/jamadermatol.2019.1783.

Autoimmune Disease

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

Lancet.

van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, Werth VP, Gordon RM, Zhou B, Hsu B, Chevrier M, Triebel M, Jordan JL, Rose S

doi: 10.1016/S0140-

Rheumatoid Arthritis

Tocilizumab modulates serum levels of adiponectin and chemerin in patients with rheumatoid arthritis: potential cardiovascular protective role of IL-6 inhibition

Clin Exp Rheumatol.

Fioravanti A, Tenti S, Bacarelli MR, Damiani A, Li Gobbi F, Bandinelli F, Cheleschi S, Galeazzi M, Benucci M

Rheumatoid Arthritis

Exposure-response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis

Rheumatology (Oxford).

Khatri A, Klünder B, Peloso PM, Othman AA

doi: 10.1093/rheumatolog/key312.

Psoriatic ArthritisSpinal Disorders

The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies

Ann Rheum Dis.

McGonagle DG, McInnes IB, Kirkham BW, Sherlock J, Moots R

doi: 10.1136/annrheumdis-2019-215356.

Psoriatic Arthritis

Response to Secukinumab on Synovitis using Power Doppler Ultrasound in Psoriatic Arthritis: 12-week Results from a Phase III Study, ULTIMATE

Rheumatology (Oxford)

D'Agostino MA, Schett G, López-Rdz A, Šenolt L, Fazekas K, Burgos-Vargas R, Maldonado-Cocco J, Naredo E, Carron P, Duggan AM, Goyanka P, Boers M, Gaillez C

doi: 10.1093/rheumatology/keab628

Related content